Sivan Gazit

Dr. Sivan Gazit

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 November 2021 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
MLMatan Levine-Tiefenbrun
Matan Levine-Tiefenbrun
IYIdan Yelin
Idan Yelin
HAHillel Alapi
Hillel Alapi
RKRachel Katz
Rachel Katz
EHEsma Herzel
Esma Herzel
RKRoy Kishony
Roy Kishony

4 November 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
BMBarak Mizrahi
Barak Mizrahi
RLRoni Lotan
Roni Lotan
NKNir Kalkstein
Nir Kalkstein
APAsaf Peretz
Asaf Peretz
GPGalit Perez
Galit Perez
TPTal Patalon
Tal Patalon
The short-term effectiveness of a two-dose regimen of the BioNTech/Pfizer mRNA BNT162b2 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine was widely demonstrated. However, long term effectiveness is still unknown. Leveraging the centralized computerized database of Maccabi Healthcare Services (MHS), we assessed the correlation between time-from-vaccine and incidence of breakthrough infection between June 1 and July 27, the date of analysis. After controlling for potential confounders as age and comorbidities, we found a significant 1.51 fold (95% CI, 1.38–1.66) increased risk for infection for early vaccinees compared to those vaccinated later that was similar across all ages groups. The increased risk reached 2.26- fold (95% CI, 1.80–3.01) when comparing those who were vaccinated in January to those vaccinated in April. This preliminary finding of vaccine waning as a factor of time from vaccince should prompt further investigations into long-term protection against different strains.

5 April 2022 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
SGSivan Gazit
Sivan Gazit
RSRoei Shlezinger
Roei Shlezinger
GPGalit Perez
Galit Perez
RLRoni Lotan
Roni Lotan
APAsaf Peretz
Asaf Peretz
TPTal Patalon
Tal Patalon
Background: Waning of protection against infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) conferred by 2 doses of the BNT162b2 vaccine begins shortly after inoculation and becomes substantial within 4 months. With that, the impact of prior infection on incident SARS-CoV-2 reinfection is unclear. Therefore, we examined the long-term protection of naturally acquired immunity (protection conferred by previous infection) compared to vaccine-induced immunity. Methods: A retrospective observational study of 124 500 persons, compared 2 groups: (1) SARS-CoV-2-naive individuals who received a 2-dose regimen of the BioNTech/Pfizer mRNA BNT162b2 vaccine, and (2) previously infected individuals who have not been vaccinated. Two multivariate logistic regression models were applied, evaluating four SARS-CoV-2-related outcomes—infection, symptomatic disease (coronavirus disease 2019 [COVID-19]), hospitalization, and death—between 1 June and 14 August 2021, when the Delta variant was dominant in Israel. Results: SARS-CoV-2-naive vaccinees had a 13.06-fold (95% confidence interval [CI], 8.08–21.11) increased risk for breakthrough infection with the Delta variant compared to unvaccinated-previously-infected individuals, when the first event (infection or vaccination) occurred during January and February of 2021. The increased risk was significant for symptomatic disease as well. When allowing the infection to occur at any time between March 2020 and February 2021, evidence of waning naturally acquired immunity was demonstrated, although SARS-CoV-2 naive vaccinees still had a 5.96-fold (95% CI: 4.85–7.33) increased risk for breakthrough infection and a 7.13-fold (95% CI: 5.51–9.21) increased risk for symptomatic disease. Conclusions: Naturally acquired immunity confers stronger protection against infection and symptomatic disease caused by the Delta variant of SARS-CoV-2, compared to the BNT162b2 2-dose vaccine-indued immunity.

9 June 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
TPTal Patalon
Tal Patalon
YSYaki Saciuk
Yaki Saciuk
APAsaf Peretz
Asaf Peretz
GPGalit Perez
Galit Perez
YLYoav Lurie
Yoav Lurie
SGSivan Gazit
Sivan Gazit
The duration of protection of the third (booster) dose of the BioNTech/Pfizer BNT162b2 mRNA Coronavirus Disease 2019 vaccine has been the subject of recent investigations, as global discussions around the necessity and effectiveness of a fourth dose are already underway. By conducting a retrospective study implementing a test-negative case-control design, analyzing 546,924 PCR tests performed throughout January 2022 by 389,265 persons who received at least two doses, we find that the effectiveness in each month-since-vaccination decreases significantly. Compared to those vaccinated five months prior to the outcome period, on August 2021, relative protection against infection waned from 53.4% a month after vaccination to 16.5% three months after vaccination. These results suggest that there is a significant waning of vaccine effectiveness against the Omicron variant of the third dose of the BNT162b2 vaccine within a few months after administration. Additional information could assist to comprehensively estimate the effectiveness of the three-dose-strategy.

27 January 2022 in Science
Verified
Journal Article
Open access
OPOttavia Prunas
Ottavia Prunas
JWJoshua Warren
Joshua Warren
FCForrest W. Crawford
Forrest W. Crawford
SGSivan Gazit
Sivan Gazit
TPTal Patalon
Tal Patalon
VPVirginia E. Pitzer
Virginia E. Pitzer
The effectiveness of vaccines against COVID-19 on the individual level is well established. However, few studies have examined vaccine effectiveness against transmission. We used a chain binomial model to estimate the effectiveness of vaccination with BNT162b2 [Pfizer-BioNTech messenger RNA (mRNA)-based vaccine] against household transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in Israel before and after emergence of the B.1.617.2 (Delta) variant. Vaccination reduced susceptibility to infection by 89.4% [95% confidence interval (CI): 88.7 to 90.0%], whereas vaccine effectiveness against infectiousness given infection was 23.0% (95% CI: −11.3 to 46.7%) during days 10 to 90 after the second dose, before 1 June 2021. Total vaccine effectiveness was 91.8% (95% CI: 88.1 to 94.3%). However, vaccine effectiveness is reduced over time as a result of the combined effect of waning of immunity and emergence of the Delta variant.

10 June 2021 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
OMOren Milman
Oren Milman
IYIdan Yelin
Idan Yelin
NANoga Aharony
Noga Aharony
RKRachel Katz
Rachel Katz
EHEsma Herzel
Esma Herzel
RKRoy Kishony
Roy Kishony